ArticleBMC cancer2025
Integrated single-cell and transcriptome sequencing data reveal the value of AOC1 in gliomas tumor microenvironment and prognosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlioma is a primary brain tumor that is frequently encountered in humans, with malignant gliomas representing an exceptionally aggressive subtype. The role of AOC1 in the progression of various human tumors has been documented; however, its involvement in gliomas (including distinct WHO grades, namely WHO Grade IV glioblastoma multiforme [GBM] and WHO Grades II–III low-grade gliomas [LGG]), remains largely unexplored.
methodsWe analyzed RNA sequencing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases to assess AOC1 expression. We performed transcriptomic analysis and differential gene expression studies based on AOC1 levels in TCGA sequencing data. Functional analyses exploring the signaling pathways involved in AOC1. CIBERSORT, single-sample Gene Set Enrichment Analysis (ssGSEA), and ESTIMATE were employed to estimate the tumor microenvironment in gliomas. Analyzing the single-cell sequencing data further revealed the value of AOC1 played in intercellular communication. Finally, the mechanism of AOC1 involvement in gliomas was verified by cellular and molecular experiments.
resultsHigh tumor expression of AOC1 is associated with lower patient survival. Our analyses revealed that cytokine signaling pathways are significantly suppressed in AOC1-high GBMLGG tissues. Q-PCR results corroborated that AOC1 inhibits IL17, IL6 and IL1β secretion in GBM cells. The CIBERSORT analysis showed a significant increase in the proportion of M2 macrophages in AOC1-high cancer tissues. Cell-cell communication analysis indicated that the MIF signaling network between AOC1-high GBMLGG tumor cells and macrophages is notably weakened. Additionally, AOC1 silencing directly delays the proliferation and migration of GBMLGG cells in vitro.
conclusionsTumor AOC1 levels can serve as a molecular marker for diagnosis and molecular subtyping. As a secreted protein, AOC1 holds promise as a new target for non-invasive molecular diagnosis and precision therapy in GBMLGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.